Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-27
2005-09-27
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S311000, C514S415000, C514S468000, C514S476000, C514S477000, C514S478000, C546S134000, C546S291000, C548S452000, C549S433000, C558S233000
Reexamination Certificate
active
06949574
ABSTRACT:
The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.
REFERENCES:
patent: 1174757 (1964-07-01), None
patent: 1232947 (1967-01-01), None
patent: 841141 (1960-07-01), None
patent: WO 90/01874 (1990-03-01), None
Levine, J. D., New Directions in Pain Research: Meeting Report Molecules to Maladies, Neuron 20: 649-654, 1998.
Pasternak, G. W., The Central Questions in Pain Perception May Be Peripheral, Proc. Natl. Acad. Sci. USA, 95:10354-10355, 1998.
Devane, W. A. et al., Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptors, Science 258: 1946-1949, 1992.
Hanus, L. et. al., Two New Unsaturated Fatty Acid Ethanolamides in Brain that Bind to the Cannabinoid Receptor, J. Med. Chem. 36: 3032-3034, 1993.
Machoulam, R. et. al., Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds To Cannabinoid Receptors, Biochem. Pharmacol. 50: 83-90, 1995.
Barg, J. et. al., Cannabinomimetic Behavioral Effects of and Adenylate Cyclase Inhibition By Two New Endogenous Anandamides, Eur. J. Pharmacol. 287: 145-152, 1995.
Richardson, J. D. et al., Cannabinoids Reduce Hyperalgesia and Inflammation Via Interaction With Peripheral CB1 Receptors, Pain 75: 111-119, 1998.
Jaggar, S.I., et al., The Anti-Hyperalgesic Actions of the Cannabinoid Anandamide and the Putative CB2 Receptor Agonist Palmitoylethanolamide in Visceral and Somatic Inflammatory Pain, Pain 76: 189-199, 1998.
Huang, S.M., et al., Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain, J. Biological Chemistry, 276: 46, 42639-42644, 2001
Richardson, J.D. et al., Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia ,J. Neurosci. 18: 451-457, 1998.
Calignano, A. et. al., Control of Pain Initiation By Endogenous Cannabinoids, Nature 394: 277-281, 1998.
Meng, I.D. et. al., An Analgesia Circuit Activated By Cannabinoids, Nature 395: 381-383, 1998.
Deng Hongfeng
Sit Sing-Yuen
Xie Kai
Bristol--Myers Squibb Company
Davis Zinna Northington
Epperson James
Makujina Shah R.
LandOfFree
(Oxime)carbamoyl fatty acid amide hydrolase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (Oxime)carbamoyl fatty acid amide hydrolase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (Oxime)carbamoyl fatty acid amide hydrolase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3380962